When I enrolled for my management course, our Economics professor at college had been teaching the subject for over three and ...

In year two of the trial, Elevidys demonstrated statistically significant and clinically improvements across three key ...

placebo-controlled randomised study with a 4-week placebo run-in period was performed. Euglycaemic hyperinsulinaemic clamp tests and 24-hour ambulatory blood pressure measurements were performed ...

After a placebo run-in period, patients were assigned to mexazolam 1mg three times daily (n = 32) or placebo (n = 28) for 21 days. Effects on psychomotor performance were evaluated with the Leeds ...

ECHELON-3 is a randomized, double-blind, placebo-controlled, active-comparator ... patients after completion of one cycle of open-label BV + Len + R in the safety run-in period, which enrolled a total ...

Roche announces positive results from EMBARK phase III study of Elevidys in ambulatory individuals with DMD: Basel Tuesday, January 28, 2025, 11:00 Hrs [IST] Roche announced posit ...

Inc. stock despite strong Phase 2b data. Click for my updated look at MNMD stock and its market opportunities.

TRUMP LOST. Vote Suppression Won. Former BBC, Guardian, etc., investigative reporter published here on Hartmann Report his ...

Securities maintained their positive outlook on Sarepta Therapeutics (NASDAQ:SRPT), reiterating an Outperform rating and a ...

The gene therapy delandistrogene moxeparvovec-rokl showed clinically meaningful benefits and disease stabilization at 2 years ...

A new study published in Nature Communications shows that oral fecal microbiota transplantation (FMT) is a feasible and safe ...

The positive results from the second part of the EMBARK trial contrast with findings from one-year post treatment, which did ...